Purpose: Commissioning beam data for proton spot scanning beams are compared for the first two Varian ProBeam sites in the United States, at the Maryland Proton Treatment Center (MPTC) and Scripps Proton Therapy Center (SPTC). In addition, the extent to which beams can be matched between gantry rooms at MPTC is investigated.
| INTRODUCTION
Proton pencil beam spot scanning is an emerging technology that is increasingly used in proton centers around the world. Spot scanning provides the ability to modulate the beam in energy as well as intensity as the dose is painted across the target. Spot scanning also negates the use of collimators and compensators, which are sources of neutron dose to the patient. Varian Medical Systems is among the latest vendors entering the proton market with their ProBeam™ spot scanning system. Two facilities in the United States currently use the ProBeam system, and several more are in different phases of construction and commissioning in the United States and Europe. 1 The first center using the Varian ProBeam system in the United States was the Scripps Proton Therapy Center (SPTC, San Diego, CA, USA). The Maryland Proton Treatment Center (MPTC) (Baltimore) was the second. With two centers and three gantries at each currently operational, we compared commissioning data to determine how well different sites can be matched. Commissioning of a spot scanning system with a synchrotron was described previously, 2 but not for a Varian ProBeam system with a cyclotron and not comparing commissioning data across sites. ProBeam systems are exclusively spot scanning systems, with no passive scattering components. Monitor unit (MU) linearity, end effects, dose rate dependence, and reproducibility for the system at MPTC are also discussed here. This study describes dosimetric commissioning tests used for the Varian ProBeam system at MPTC and SPTC and provides results that can be used as a reference for future ProBeam sites. Although the tests described here are not complete, they are similar to those used before [2] [3] [4] and should provide useful benchmarks.
| ME TH ODS AND MATERIALS
The treatment planning system (TPS) used by both sites is the Varian Eclipse v11, and the treatment machine software version is ProBeam v2.7. To commission the pencil beam proton convolution superposition dose model for the TPS the integrated depth dose curves (IDDs), absolute dose calibration, and spot profiles in air had to be measured, as outlined by the Eclipse reference manual. A complete description of the dose model is given in the Eclipse V11 Proton Algorithm Reference Guide. 5 These measurements were compared for the two facilities.
The TPSs were then verified by dosimetric validation of various test plans, similar to what is suggested in reports from the American Association of Physicists in Medicine and others. [6] [7] [8] Data from the first clinical gantry were used to commission the TPS beam model at MPTC.
All subsequent gantries at MPTC were compared to the initial data to determine dosimetric equivalence.
2.A | Beamline
The Varian ProBeam system exclusively uses spot scanning gantries that dynamically scan the beam from one spot to another (if distances between spots are less than a few millimeters). The system uses a superconducting isochronous cyclotron with an azimuthally varying field to accelerate hydrogen nuclei. This technology allows proton acceleration to 250 MeV with a maximum of 800-nA extracted current at the exit of the cyclotron. The energy is then modulated continuously (as opposed to a synchrotron system, where the energy is changed discretely) by a double-carbon wedge degrader system, which can reduce the energy continuously to 70 MeV.
Typically a current of 1-2 nA is used during patient treatment, but nozzle current can be as high as 10 nA. Beam losses in the energy selection system can range from 98% (250 MeV) to 99.75%
(70 MeV). 9 The beam nozzle contains two steering magnets for the beam, a kapton window to seal the vacuum, an MU chamber, and a strip ionization chamber to verify the beam position. The center of the y-steering magnet is at 256 cm and the x-steering magnet at 200 cm. A source-to-isocenter distance of 228 cm is thus used in the TPS. The maximum field size is 30 (x) by 40 (y) cm at isocenter, where the y axis is aligned in the craniocaudal direction in a Head first supine (HFS) patient with the table at the nominal treatment position. A range shifter can be inserted into the snout, and the snout can move continuously from 3 to 42 cm from the isocenter.
The gantry can rotate 360°, and the couch can rotate from 265°to 95°, with 0°as the nominal position. For pitch and yaw 3°are allowed clinically. The planned energy layer switch time is <1 s, and the minimum time to deliver the minimum weighted spot per energy layer is~3 ms. The spot with the smallest number of MUs needed per layer will thus determine the dose rate. The smallest sigmas of the spots are~4 mm in air at isocenter.
The MPTC has four gantry rooms (TR1, TR2, TR3, and TR4) and one fixed-beam room. SPTC has three gantry rooms and two fixedbeam rooms. SPTC data used here for comparison reflect average data for all their gantries after commissioning.
2.B | Measuring Bragg peaks
The IDDs were acquired with a PTW Bragg peak chamber (PTWFreiburg, Germany) in a 3D water tank at both sites. The Bluephantom2 (IBA Dosimetry, Schwarzenbruck, Germany) was used at MPTC and the PTW 3D water tank (PTW-Freiburg, Germany) at SPTC. The measuring field diameter of the Bragg peak chamber is 8. The chambers are spaced 2 mm apart. The Giraffe was also used to verify the WETs of the reference chamber, the range shifters, and the water tank window.
2.C | Absolute calibration
The absolute output of the unit was measured using the methodol- The water tank was moved to place the isocenter at the effective point of measurement of the chamber to eliminate the need for a source-to-axis-distance correction, and a gantry angle of 0°was used for these measurements. The corresponding IDDs at MPTC for each energy were then scaled according to this measurement at a 2-cm depth for import into the planning system in units of Gy.mm 2 /MeV.
Relative biological effectiveness (RBE) was chosen as 1.1 and was incorporated in our planning system through a depth-dose normalization 2.E | MU linearity (tolerance: ≤2% for >5 MU and
For MU linearity, monitor end effect, and dose rate dependence, a PPC05 parallel-plate ion chamber was used in water. The chamber's effective point of measurement was placed at a 2-cm depth. Dose rates used for linearity measurements were 60,000 MU/min for 70 MeV, 500,000 MU/min for 160 MeV and 200,000 MU/min for 240 MeV for MU settings of 2, 5, 50, 100, 500, 1,000, 2,500, 5,000, and 10,000 MU, for a monoenergetic pencil beam on the central axis. Readings were normalized to the 100-MU reading for each energy.
2.F | Monitor end effect (tolerance: ≤3 MU for 3,000 MU deliveries [0.1%])
The dose rate used was 60,000 MU/min, and the end effect was measured for 70, 160, and 240 MeV for a complete delivery of 3,000 MU and a delivery of 3,000 MU in three separate 1,000-MU deliveries. The end effect was calculated by assuming that ionization M in general is proportional to the sum of n times the set number of monitor units and n times the end effect (T E ), expressed as:
where T is the total number of MUs, M 1 is the measurement with no interruptions, and M 3 the measurement with n = 3 interruptions.
The end effect was also calculated by fitting a linear regression through the data measured for the linearity.
2.G | Dose rate dependence (tolerance: ≤2%)
A fixed dose of 2,000 MU was delivered with a monoenergetic pencil beam on the central axis for 70 and 160 MeV and 500 MU for 240 MeV. Different dose rates were used for each energy (i.e.,
T A B L E 1 Data measured with the IBA 3D water tank and a PTW 34070 ion chamber (TR4 and TR3) and a Stingray ion chamber (TR1), comparing TR1 with TR4 and TR3 with TR4. Theoretical values for each energy were calculated from the Bortfeld equation (R 80 = 0.002449E 1.75 6,500, 50,000, 100,000, 1,000,000, 5,000,000 MU/min for 70 MeV; 50,000, 100,000, 750,000, 1,500,000, 3,000,000 MU/min for 160 MeV; and 10,000, 20,000, 40,000, 80,000, 250,000, and 500,000 MU/min for 240 MeV). Values were normalized to the maximum delivered dose rate for each energy. The number of MUs had to be decreased for higher energies to reduce the current of the proton beam at isocenter. These dose rates cover the clinically expected dose rates.
2.H | Output vs gantry angle (tolerance: ≤1%)
A small-volume CC04 ion chamber (IBA Dosimetry) was used inside a 5-cm WET buildup cap attached to the edge of the couch. The gantry was rotated to the four cardinal gantry angles. Plans with spots covering a 10 9 10-cm 2 monoenergetic plane were delivered for 70, 160, and 240 MeV. Spot spacing in these plans was 2.5 mm, and each spot was equally weighted. Values were normalized to the measurements at gantry = 0°. A dose rate of 60,000 MU/min was used for all energies, and 10,000 MUs were delivered at each angle.
2.I | Reproducibility and interrupted treatment
(tolerance: Less than larger of 0.5 cGy or 1% of delivered dose)
The gantry was placed at 0°, and the Matrixx PT (IBA dosimetry) planar ion chamber array was placed at the isocenter with a 5-cm buildup (5.4-cm WET) added to place the measuring point at 6 cm.
Three plans were delivered with different ranges and spread-out Bragg peaks (SOBPs) to cover a wide range of energies. Each plan covered a 26 9 26-cm 2 surface to a dose of 500 cGy for varying SOBPs (i.e., R8S4, R15S7, and R22S7, where R represents the nominal range in centimeters and S the length of the SOBP in centimeters). Each plan was delivered three times, and doses at the central chamber were recorded and compared.
To test an interrupted treatment, arbitrary fields were repeatedly delivered on the Matrixx PT array. For the first delivery, the complete field was delivered uninterrupted. For the second field, treatment was interrupted at approximately halfway and then restarted.
Profiles for these measurements were compared and analyzed.
2.J | Test plans
Verification plans were run at MPTC to verify the TPS. Plans were show that all differences were <1% for both for energies >80 MeV.
For 80 MeV the differences in R 80 were the largest at 1.74% for TR1, compared to TR4, and 1.55% for TR3, respectively, corresponding to 0.9 and 0.8 mm differences in range in water.
IDDs for the MPTC gantries were also compared with those from SPTC. The data were in good agreement ( However, for higher energies the IDDs in the shoulder region for TR1 (larger chamber) are slightly higher than those for TR4 (smaller chamber), suggesting that the chamber is not large enough for these higher energies to capture all secondary protons in the halo. This agrees with data from Monte Carlo studies on the halo effect.
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The increase in dose of the SPTC data was on average 4.5% higher for lower energies compared to that of MPTC. SPTC introduced Monte Carlo-modeled data into their data which take the halo effect more accurately into account. However, this difference occurs in the plateau region, which is only~25% of the maximum dose (i.e., the effect is more on the order of~1% if this region contributes dose to the target volume). We observed no marked differences in comparisons of the TPS plans with measured data inside the planning target volume. This increase in the plateau region decreased as energy increased, and there was no marked difference for energies >180 MeV.
Distal penumbra between R 80 and R 20 in the distal edge of the Bragg peak measured with the Giraffe MLIC are shown in Table 2 for each of the MPTC gantries. These values were also acquired with the water tank and the Bragg peak chamber and are shown in Fig. 2 .
The tolerance used was: <0.2 g/cm 2 each energy. The differences between the values measured for TR1
and TR3 compared to TR4 were all <0.03 cm.
The sharpest distal fall-off occurred for the lower energies because of less range straggling. The effect of the carbon energy degrader is evident from the almost constant slope for energies >180 MeV. This was first described by Hsi et al. 17 and is only evident in systems with an energy degrader and energy selection slit. This is caused by the increased spread in the energy spectrum for lower energies caused by the degrader. If the full-energy spread generated in the degrader is transported to the treatment location, the width of the peak measured in water should be constant as a function of range. The introduction of the energy slit to reduce the spread in energy causes this continued decrease as the range decrease below 180 MeV. The width of the slit will thus determine where this transition from a constant to a decreasing slope will occur and is fixed for all Varian ProBeam systems. Above 180 MeV the full-energy spectrum is transported but not below that, causing range straggling to become dominant.
3.B | Absolute calibration
Measured absolute doses as functions of energy are shown in Fig. 3 for each gantry as well as for SPTC. The SPTC doses were normalized at 160 MeV to that of the TR4 to eliminate any discrepancies between MPTC calibration and that of SPTC. The absolute doses for the gantries at MPTC and SPTC are all within 1% of those measured for TR4. The doses of TR4 were used in the TPS. After commissioning of the Eclipse treatment planning system, doses were recalculated for the same setup used during measurement. The TPS calculated doses were then compared with the measured doses to quantify discrepancies between the TPS and measurements. Measured values of the MPTC gantries were all within 1.5% from those of the TPS, except for 245 MeV, which was at 2.7% for all gantries.
Calibration of the monitor ion chamber in the snout had to be adjusted for TR3 to achieve better agreement with TR4 values.
The decrease in the output as a function of energy and the eventual slight increase for energies >140 MeV can be attributed to the energy slit, which is used to keep energy dispersion low after the degrader, similar to earlier descriptions. Fig. 4 . The FWHM of the profiles is slightly larger for SPTC and TR1 than TR4 at higher energies and smaller at lower energies, but within the 15% tolerance compared to each other. Profiles with the 5-cm range shifter inserted also agree well. In Table 3 found to have no impact within differences of 20% at high energies (corresponding to~0.8 mm in r).
3.C.2 | Spot symmetry (Tolerance: ≤5%) Table 4 shows symmetry between r x and r y for TR1, TR3, and TR4.
The largest asymmetries are found for TR1, with a maximum of 4.09% at 245 MeV. For TR3 the maximum is 3.04% at 150 MeV, and for TR4 3.56% at 240 MeV.
3.D | MU linearity
Monitor unit linearity was found to be within tolerance (≤2% for >5 MU and ≤5% for ≤5 MU) for all gantries and for each energy delivered. Ratios were <1% for 70 MeV and increase as the energy increases. The minimum MU that can be delivered per spot at MPTC is 1 MU. This still gives an acceptable accuracy, because spots delivering the minimum MU are mostly a fraction of the overall number of spots in a treatment plan.
3.E | Monitor end effect
Results for the end effect calculated with equation 1 are all within the 0.1% tolerance (≤3 MU here) given by TG142. 6 Note that a negative value for the x-intercept implies too much dose was delivered during start and termination of the beam, whereas a positive intercept implies underdosing caused by ramp-up of the dose. This is opposite from the sign interpretations given by the method using equation 1.
The x-axis intercepts of the lines fitted through the MU linearity data were all within tolerance for TR1, TR3, and TR4, with a maximum of -2.45 MU for 240 MeV.
3.F | Dose rate dependence
Dose rate dependence was within 0.3% for all energies and dose rates tested for TR1, TR3, and TR4.
3.G | Output vs gantry angle
Output variation with gantry angle was <0.3% for TR3 and TR4 for all energies measured. For TR1 it was larger than the tolerance of 1% for 240 MeV. The maximum was 1.6% for 240 MeV.
3.H | Reproducibility and interrupted treatments
All doses were within 1 cGy of each other (which is 0.2% of the planned dose) for the same plans delivered repeatedly. The profiles agreed within 1%/1 mm for 100% of the points. For the interrupted treatment the profiles agreed within 1%/1 mm for 96% of the points. Profiles across the interruption show a decrease in dose of 1.1%. This was repeated two times, and the average of the maximum dose difference was a decrease of 0.8%.
3.I | Test plan comparison
The distribution of percentage differences between the point doses for the test plans calculated with the TPS and those measured are shown in Fig for TR1, TR3 , and TR4. For TR1 90% of the planned and measured doses agreed within 2.5%. For TR3 and TR4 90% of the doses agreed within 2.75%.
The distribution of percentage differences between point doses for the test plans measured for TR4 and those for TR1 and TR3
show similar trends. For the TR4-TR1 comparison 90% of planned and measured doses agreed within 2.9%, and for the TR4-TR3 comparison 90% of the agreed within 2.75%.
The distribution of measurements was skewed higher than the calculated TPS doses for TR4 for a majority of the plans. For TR1, measurements were more evenly distributed across an average of 0%. 
| CONCLUSION
We found reasonable agreement between the TPS and measurements without using a double Gaussian function to model the spot profiles in the TPS as suggested by other authors. 1, [13] [14] [15] [16] Although this was surprising, including a double Gaussian function in the TPS model did not markedly increase agreement between measured and calculated data from the TPS. The same beam model could be used to model all the MPTC gantries, and the machines were declared dosimetrically equivalent. We also showed agreement between spot profiles and IDDs measured at different sites for this system.
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R E F E R E N C E S
T A B L E 4 Symmetry: |(r x -r Y )|/(r x +r Y )*100 (%) for MPTC gantries TR1, TR3, and TR4 for each energy between the spot rs at a gantry angle of 0°at isocenter. 
